LONG MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 05:13:34 27/06/2024 pm IST | ||
| 7.22 EUR | +1.12% |
|
| Current month | -21.62% | ||
| 1 month | -22.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 7.22 | +1.12% |
| 26/24/26 | 7.14 | +0.99% |
| 25/24/25 | 7.07 | -0.70% |
| 24/24/24 | 7.12 | -0.84% |
| 20/24/20 | 7.18 | +5.74% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 05:13 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VE93FM |
| ISIN | DE000VE93FM2 |
| Date issued | 17/03/2020 |
| Strike | 1,256 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 29.33 € |
|---|---|
| Lowest since issue | 1.44 € |
| Spread | 0.02 € |
| Spread % | 0.27% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,791
DKK
Average target price
2,464
DKK
Spread / Average Target
+37.58%
- Stock Market
- Certificates
- Certificat
